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 LEADER-4: blood pressure control in patients with
type 2 diabetes and high cardiovascular risk: baseline
data from the LEADER randomized trial
John R. Petriea, Steven P. Marsob, Stephen C. Bainc, Edward Franekd,e, Stephan Jacobf,
Luis Masmiquelg, Lawrence A. Leiterh, Martin Haluziki, Ilhan Satmanj, Mohamed Omark,
Marina Shestakoval,m, Luc Van Gaaln, Johannes F. Manno, Florian M.M. Baeresp, Bernard Zinmanq,
Neil R. Poulterr, on behalf of the LEADER investigators
Objective: As glucagon-like peptide-1 receptor agonists
lower blood pressure (BP) in type 2 diabetes mellitus
(T2DM), we examined BP control in relation to targets set
by international bodies prior to randomization in the
Liraglutide Effect and Action in Diabetes: Evaluation of
cardiovascular outcome Results (LEADER) trial.
Methods: We analyzed baseline data from LEADER
(NCT01179048), an ongoing phase 3B, randomized,
double-blind, placebo-controlled cardiovascular outcomes
trial examining the cardiovascular safety of the glucagon-
like peptide-1 receptor agonist liraglutide in 9340 people
with T2DM from 32 countries [age (all mean SD)
647.2 years, BMI 32.56.3 kg/m2, duration of diabetes
12.7 8.0 years], all of whom were at high risk for
cardiovascular disease (CVD).
Results: A total of 81% (n¼7592) of participants had
prior CVD and 90% (n¼8408) had a prior history of
hypertension. Despite prescription of multiple
antihypertensive agents at baseline, only 51% were
treated to a target BP of less than 140/85mmHg and only
26% to the recommended baseline BP target of less than
130/80mmHg. In univariate analyses, those with prior CVD
were prescribed more agents (P<0.001) and had lower BP
than those without (13718.8/7810.6mmHg versus
14017.7/809.9mmHg; P<0.001). In logistic
regression analyses, residency in North America (64%
treated to <140/85mmHg; 38% treated to <130/
80mmHg) was the strongest predictor of BP control.
Conclusion: These contemporary data confirm that BP
remains insufficiently controlled in a large proportion of
individuals with T2DM at high cardiovascular risk,
particularly outside North America. Longitudinal data from
the LEADER trial may provide further insights into BP
control in relation to cardiovascular outcomes in this
condition.
Keywords: blood pressure, cardiovascular disease,
glucagon-like peptide-1, regional differences, targets, type
2 diabetes mellitus
Abbreviations: CVD, cardiovascular disease; eGFR,
estimated glomerular filtration rate; GLP-1, glucagon-like
peptide-1; LEADER, liraglutide effect and action in
diabetes, evaluation of cardiovascular outcome results;
SGLT-2, sodium–glucose linked transporter-2
INTRODUCTION
A
s blood pressure (BP) control is an important
strategy for preventing cardiovascular and renal
complications in type 2 diabetes mellitus (T2DM)
[1,2], some treatment guidelines include disease-specific BP
targets [3,4]. However, these can be difficult to achieve,
even with multiple antihypertensive agents [5,6].
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Original Article
Liraglutide Effect and Action in Diabetes: Evaluation of
cardiovascular outcome Results (LEADER) is an ongoing
phase 3B global cardiovascular outcome trial examining the
cardiovascular safety and potential benefits of the gluca-
gon-like peptide-1 (GLP-1) analogue liraglutide in individ-
uals with T2DM at high risk of cardiovascular disease (CVD)
[7]. The primary objective is to assess the effect of treatment
with liraglutide comparedwith placebo (for at least 3.5 years
and up to 5 years) on the incidence of cardiovascular
events, as defined by the primary end point of cardiovas-
cular death, nonfatal myocardial infarction, or nonfatal
stroke in adult patients with T2DM.
The efficacy of BP-lowering agents is not greatly influ-
enced by BMI [8], but as BMI and BP are closely associated
[9], more agents are required to achieve BP targets in obese
individuals [8]. In T2DM, this therapeutic challenge is
compounded by weight gain in association with many
commonly used glucose-lowering agents (insulin, sulpho-
nylureas, and thiazolidinediones) [10,11]. In the UK
Prospective Diabetes Study, in which patients with T2DM
had a BMI 29.8 5.5 kg/m2 (mean SD) and a very con-
servative definition of ‘tight’ BP control (<150/85mmHg),
29% still required three or more antihypertensive agents [1].
Glucose-lowering agents that have been introduced
more recently either do not affect weight (e.g., dipeptidyl
peptidase-4 inhibitors) [10,11] or are associated with weight
reduction [e.g., GLP-1 receptor agonists [10,12]; sodium–
glucose linked transporter-2 (SGLT-2) inhibitors] [13]. When
added to another glucose-lowering therapy, liraglutide
treatment is associated with weight reduction of 1.2–
2.6 kg and SBP reduction of 2.3–6.7mmHg [14–18]. It
therefore has the potential to facilitate the achievement
of BP targets in overweight and obese patients already
being treated with multiple agents.
In the present study, we analyzed baseline data from the
LEADER trial to: describe BP control at the time of random-
ization; report rates of nonachievement of BP targets in
relation to contemporary and updated guidelines; and
determine the factors predicting nonachievement of targets
prior to randomization to liraglutide or placebo. During
the trial recruitment period (2010–2012), international
guidelines recommended a BP target of <130/80mmHg
in T2DM [3,4].
Prompted by initial analyses, we also examined BP
control categorized according to the geographical regions
represented in the trial.
RESEARCH DESIGNANDMETHODS
The LEADER study design and baseline characteristics have
been published previously [7]. Briefly, participants were
enrolled between September 2010 and April 2012 at
410 sites in 32 countries according to the following
inclusion criteria: patients with T2DM aged at least 50 years
with concomitant CVD, cerebrovascular disease, peripheral
vascular disease, chronic renal failure, or chronic heart
failure; or patients aged at least 60 years with one or more
of the following cardiovascular risk factors: microalbumi-
nuria or proteinuria, hypertension, and left ventricular
hypertrophy by ECG or imaging, left ventricular dysfunc-
tion by imaging, or ankle–brachial index less than 0.9. All
patients had baseline HbA1c at least 7.0% (53mmol/mol).
Exclusion criteria included type 1 diabetes mellitus, calci-
tonin at least 50 ng/l, use of GLP-1 receptor agonists,
dipeptidyl peptidase-4 inhibitors, or insulin preparations
other than human neutral protamine Hagedorn, long-acting
analogs, or premixed preparations within 3 months prior
to screening.
BP was measured at the screening visit following usual
practice for clinical research at each individual trial center,
with adherence to the following standards as a minimum.
Participants were asked to avoid caffeine, smoking, and
exercise at least 30min before measurement. Measure-
ments were taken with the participant in a sitting position,
with the legs uncrossed, and the back and arm supported.
Participants were sitting for at least 5min before the first
reading was taken. Two measurements at intervals of at
least 2min were performed. Participants and trial personnel
were advised not to talk during the measurements. The
manufacture and model of the semi-automated measure-
ment devices and the cuff sizes used were not recorded.
The mean of the two BP measurements was subsequently
calculated for use in analyses. In some individuals (<1%)
for whom measurements were not available from the
screening visit, those from the randomization visit were
used. Hypertension was defined as SBP at least 140mmHg,
a DBP at least 90mmHg, or an existing prescription of
antihypertensive medication.
A target BP of less than 130/80mmHg, as recommended
by the international authorities cited above [3,4,19], was
disseminated to all study sites as the LEADER Global Expert
Panel’s ‘Standard of Care’ guideline and was therefore the
principal target used in this analysis [7]. However, owing to
subsequent changes in BP target recommendations, we also
report achievement of targets according to the updated
European Societies of Hypertension and Cardiology 2013
target of 140/85mmHg [20] and the American Diabetes
Association 2015 target of less than 140/90mmHg [21].
Resistant hypertension was defined as prescription of four
or more antihypertensive agents (or for thosewith BP>140/
90mmHg, the prescription of three or more agents) [21].
Sites were grouped as being from: North America [USA
and Canada (n¼ 2821)]; Europe (Czech Republic, Poland,
Romania, Austria, Belgium, Denmark, Finland, France,
Germany, UK, Greece, Ireland, Italy, the Netherlands,
Spain, Sweden, Turkey, and Serbia; n¼ 3521); and other
[i.e. countries not easily grouped into geographical regions
(India, China, South Korea, Taiwan, South Africa, Australia,
Brazil, Mexico, Arab Emirates, Russia, and Israel; n¼ 2998)].
All study participants gave written informed consent.
The trial (NCT01179048) was approved by the relevant local
ethical committees and is being conducted in conformity
with the Declaration of Helsinki.
Statistical analysis
Distributions of continuous variables are described
by mean SD whereas categorical variables are listed as
numbers and percentages (%). Associations of prior CVD
status and global region with covariates and factors of
interest were screened using Fisher’s exact test and F-test,
respectively. Multiple logistic regression models were
developed to assess the association between dichotomized
Blood pressure control in type 2 diabetes
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uncontrolled hypertension end points and predefined
explanatory factors. Variable selection was decided on
before model fitting. Covariates were selected by consider-
ation of potential impact on hypertension ‘off-target’
measurements, based on review of the literature and
availability in the LEADER database. Main effects of all
covariates/factors were retained in the model, as the ample
sample size of the LEADER study allowed no need
for further variable selection. Statistical analyses were
performed using SAS 9.3 software (SAS Institute, Cary,
North Carolina, USA). Analyses were performed using data
available after the trial recruitment phase, which may be
subject to minor changes following closure of the database
at trial completion.
RESULTS
A total of 91% of LEADER participants, all of whom had
T2DM, were also hypertensive. In all 61% (n¼ 5665) of
LEADER participants were prescribed two or more, and
19% (n¼ 1811) three or more antihypertensive agents.
However, at the time of the baseline visit, only 51% were
treated to a target of less than 140/85mmHg and 26% to a
target of less than 130/80mmHg.
BP was lower in those who had prior CVD (81% of the
study population) in comparison with those who had not
(137 18.8/78 10.6mmHg vs. 140 17.7/80 9.9mmHg;
P<0.001). A higher proportion of these individuals
achieved recommended targets: 52 versus 44% for a target
BP of less than 140/85mmHg and 28 versus 21% for a target
BP of less than 130/80mmHg (both P< 0.001), presumably
reflecting the use of more antihypertensive agents (3 in
20.9 vs. 13.0%; P< 0.001). Those with prior CVD were
younger (63.9 7.6 vs. 65.8 5.2 years; P< 0.001) with a
higher proportion being men and White (Table 1, left hand
panel); estimated glomerular filtration rate was lower
(79.2 28.5 vs. 91.6 23.1ml/min per 1.73m2; P< 0.001)
although positive microalbuminuria status was less preva-
lent (13.9 vs. 48.6%; P< 0.001). HbA1c, duration of diabe-
tes, and BMI were similar between the groups with and
without prior CVD.
BP was higher in European participants (141 18.3/
79 10.2mmHg) than in those from North America
(133 18.1/75 10.5mmHg; P< 0.001) and other
countries (139 18.8/80 10.2mmHg) (P< 0.0001 for
both SBP and DBP), even though more were prescribed
three or more antihypertensive agents (23.0 vs. 19.0 vs.
16.0%, respectively; P< 0.001) (Table 1). BP target was
achieved in more participants in North America and other
countries than in Europe, that is, 63 vs. 48 vs. 42%,
respectively, for less than 140/85mmHg (P< 0.0001) and
38 vs. 23 vs. 20%, respectively, for less than 130/80mmHg
(P< 0.0001). Rates of achievement of BP control in indi-
vidual countries within the regional categories are shown in
Supplementary Table 1, http://links.lww.com/HJH/A595;
rates of SBP and DBP control individually are shown in
Supplementary Table 2, http://links.lww.com/HJH/A595.
BMI was higher in participants from North America than
in those from Europe and other countries (34.5 6.8 vs.
32.7 5.7 vs. 30.4 5.8 kg/m2; P< 0.0001); estimated glo-
merular filtration rate was lower (78 26.6 vs. 83 26.6 vs.
84 30.3ml/min per 1.73m2; P< 0.0001) and a higher
proportion were Black (17 vs. 0.5 vs. 9.6%; P< 0.0001).
However, resistant hypertension was present in a higher
proportion of Europeans compared with those from North
America and other countries (15.7 vs. 9.0 vs. 10.2%;
P< 0.0001). Documented duration of diabetes was shorter
in European than in North American and other participants
(11.6 7.4 vs. 13.5 8.6 vs. 13.3 8.0 years; P< 0.0001)
and HbA1c was lower (8.3 1.3 vs. 8.7 1.5 vs. 9.0 1.7%;
P< 0.0001). The prevalence of prior CVD did not differ
among participants recruited in North America and Europe
and similar proportions within each region were receiving
insulin treatment (Table 1).
In logistic regression analyses restricted to participants
prescribed at least one antihypertensive agent (and there-
fore operationally defined as having hypertension), the
strongest predictor of achievement of a BP target of either
less than 130/80mmHg (Fig. 1), less than 140/85mmHg
(Fig. 2), or less than 140/90mmHg (Fig. 3) was residence in
North America.
DISCUSSION
These baseline data from the ongoing LEADER trial provide
a cross-sectional description of BP control in a large cohort
of individuals across global regions with long-standing
T2DM and a high risk of CVD. At the time of randomization
to liraglutide or placebo, the prevalence of hypertension
(90%) was higher than in any other recent landmark trial of
glucose-lowering therapy in T2DM (as shown in Table 2),
though a proportion will have been misclassified as hyper-
tensive because of prescription of antihypertensive agents
for other indications. Nevertheless, despite this likely
degree of misclassification, we report that BP measure-
ments met the contemporary target set by most inter-
national bodies (<130/80mmHg) in only one-quarter
of participants.
LEADER was designed so that participants could be
recruited in either primary or secondary CVD prevention
categories: major baseline characteristics have already been
reported separately for these groups [7]. The present
analysis adds more detail to the previous report, giving
BP measurements in relation to treatment and targets.
In unadjusted analyses, BP was better controlled in
secondary prevention participants (who formed 81% of
the total) than in those in the primary prevention category;
this was in keeping with apparently more intensive
pharmacological management. These findings are consist-
ent with recently-reported baseline data from the secondary
prevention study entitled Trial Evaluating Cardiovascular
Outcomes with Sitagliptin (TECOS study) in which a higher
proportion of participants who met the inclusion criteria
because of previous myocardial infarction were treated to a
target BP of less than 140/80mmHg than in those with
peripheral arterial disease but no prior cardiovascular event
[29]. In LEADER, hypertension was one of the comorbidities
specified for inclusion in the primary prevention category;
this was one of the criteria selected to ensure that those
randomized were at sufficient risk of CVD to provide
adequate statistical power for the safety and efficacy end
points. This may account, at least in part, for the apparently
Petrie et al.
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higher levels of baseline BP observed in this group. It
should be noted that the presence or absence of CVD
was not a significant determinant of BP in fully adjusted
analyses. Nevertheless, in both primary and secondary
prevention groups, there remained considerable scope
for treatment intensification, as only 21 and 13%, respec-
tively, were prescribed three or more antihypertensive
agents.
Participants recruited in European centers and other
countries had higher BP than those recruited in North
America (by mean SBP and DBP 8/4mmHg and 6/5mmHg,
respectively), although they were prescribed more antihy-
pertensive agents, had lower BMI (by 2 kg/m2 and 4 kg/m2,
respectively), and included fewer Black participants
(usually considered to be more likely to be treatment
resistant) [30]. Differences according to region of recruit-
ment did not appear to be accounted for by differences in
the demographic factors recorded.
Regional differences in control of BP have previously
been reported from population-based surveys. In general,
these have been consistent with the present observations,
namely that BP levels in Europe are on average higher than
in North America, particularly the USA [31,32]. These differ-
ences are not considered an artifact of method of measure-
ment or case selection in that higher prevalence of
hypertension at the population level is closely correlated
with higher rates of stroke mortality [31]. In surveys of
individuals without diabetes there can be higher rates of
case-finding in some countries (e.g. the US) than others,
biasing the mean BP of the treated population toward a
ASA
Statin
ARB
ACEi
Beta blocker
Macroalbuminuria
Microalbuminuria
Number of antihypertensives per medication
Insulins
Race white
Race other
Race black
Prior CVD
Region United States
Region other
Region Europe
Never smoked
Previous smoker
Current smoker
eGER <30 mI/min/1.73 m2
eGER ≥90 mI/min/1.73 m2
eGER 30–60 mI/min/1.73 m2
eGER 60–90 mI/min/1.73 m2
Female
Male
LDL per mmoI/L
HDL per mmoI/L
Totel cholesterol per mmoI/L
Creatinine per µmoI/L
Diabetes duration per 5 years
HbA 1c per %
BMI per 5 kg/m2
Age per 5 years
0.25 0.5 1 2 4
0.977 0.872; 1.093 0.6853
<0.0001
<0.0001
<0.0001
0.0745
0.0004
0.3259
0.3652
0.1600
0.2272
0.9131
<0.0001
<0.0001
<0.0022
<0.0001
0.8683
0.1780
0.6360
0.0535
0.8502
0.0956
0.0070
0.5612
0.1921
0.2708
0.2472
0.0060
0.0328
0.624; 0.833
0.711; 1.016
0.624; 0.873
0.561; 0.753
0.888; 1.451
1.013; 1.349
1.320; 1.597
1.854; 1.060
0.929; 1.620
0.928; 1.383
0.837; 1.171
1.785; 2.399
2.063; 2.677
0.737; 0.935
0.554; 0.782
0.491; 1.817
0.412; 1.170
0.472; 1.573
0.997; 1.317
0.831; 1.164
0.971; 1.451
1.058; 1.422
0.996; 1.002
0.944; 1.012
0.984; 1.059
0.982; 1.075
1.016; 1.102
0.722
0.850
0.738
0.650
1.131
1.168
1.451
1.951
1.000
1.221
1.131
1.991
1.000
2.068
2.350
1.000
0.830
0.658
1.000
0.946
0.699
0.865
1.000
1.146
0.984
1.186
1.226
0.999
0.977
1.021
1.027
1.058
Odds ratio LCL; UCL P-value
–
–
–
–
–
FIGURE 1 Odds ratios for characteristics associated with blood pressure target of >130/80mmHg at baseline in the LEADER trial. ACEi, angiotensin-converting-enzyme
inhibitor; ARB, angiotensin receptor blockers; ASA, acetylsalicylic acid; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate;
HDL, high-density lipoprotein; LCL, lower confidence interval; LDL, low-density lipoprotein; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular
outcome Results; UCL, upper confidence interval.
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lower level; this is unlikely to explain the present results, as
all participants were known cases of T2DM under routine
monitoring of BP. Neither can the differences be readily
explained by treatment intensity as the number of antihy-
pertensive agents prescribed per individual was similar in
Europe and the US [33].
Higher BP at the population level in Europe may not be
explained entirely by treatment effects, in that differences
can be observed even in young adults (few of whom have a
diagnosis of hypertension or are on BP-lowering treat-
ment): therefore, other environmental and/or genetic fac-
tors must also play a role [31]. Differences in BP in the
background populations from which participants were
drawn may have been reflected in the cohort randomized
in LEADER, but we acknowledge that the differences we
report may also, at least in part, have reflected differences in
sampling strategies among recruitment centers in Euro-
pean, North American, and other countries. Moreover,
we cannot exclude a higher prevalence of nonadherence
to therapy, more frequent prescription of less-effective
therapy, or more frequent use of subtherapeutic dosages
in European LEADER participants. There may also have
been a lower prevalence of treatment-refractory hyperten-
sion amongst North American participants.
After the completion of recruitment into LEADER,
BP targets were relaxed to less than 140/85mmHg by the
European Societies of Hypertension and Cardiology in 2013
[34]; they were then revised to less than 140/90mmHg by
the US Joint National Committee (JNC 8) [35] and the
American Diabetes Association [36]. Even before
ASA
Statin
ARB
ACEi
Beta blocker
Macroalbuminuria
Microalbuminuria
Number of antihypertensives per medication
Insulins
Race white
Race other
Race black
Prior CVD
Region United States
Region other
Region Europe
Never smoked
Previous smoker
Current smoker
eGER >30 mI/min/1.73 m2
eGER ≥90 mI/min/1.73 m2
eGER 30–60 mI/min/1.73 m2
eGER 60–90 mI/min/1.73 m2
Female
Male
LDL per mmoI/L
HDL per mmoI/L
Totel cholesterol per mmoI/L
Creatinine per µmoI/L
Diabetes duration per 5 years
HbA 1c per %
BMI per 5 kg/m2
Age per 5 years
0.25 0.5 1 2 4
0.957 0.867; 1.056
0.736; 0.934
0.803; 1.093
0.712; 0.955
0.608; 0.785
1.035; 1.582
1.055; 1.349
1.295; 1.520
0.850; 1.030
1.113; 1.779
0.931; 1.328
0.800; 1.060
1.649; 2.145
2.037; 2.582
0.827; 1.019
0.731; 1.003
0.536; 1.727
0.482; 1.215
0.486; 1.421
0.912; 1.165
0.912; 1.226
0.986; 1.392
0.987; 1.280
0.998; 1.003
0.960; 1.022
0.992; 1.058
1.015; 1.100
1.036;1.113
0.3828
0.0020
0.4083
0.0098
<0.0001
<0.0001
<0.0001
<0.0001
0.0001
0.0230
0.0050
0.1767
0.0043
0.2431
0.2485
0.1087
0.0544
0.8937
0.2564
0.4959
0.6275
0.4596
0.0724
0.0774
0.7003
0.5447
0.1383
0.0071
0.829
0.937
0.834
0.691
1.279
1.193
1.403
1.936
1.000
1.406
1.112
0.920
1.000
1.880
2.293
1.000
0.918
0.856
1.000
0.961
0.765
0.830
1.000
1.031
1.057
1.171
1.124
1.001
0.991
1.025
1.057
1.074
Odds ratio LCL; UCL P-value
–
–
–
–
–
FIGURE 2 Odds ratios for characteristics associated with blood pressure target of >140/85mmHg at baseline in the LEADER trial. ACEi, angiotensin-converting-enzyme
inhibitor; ARB, angiotensin receptor blockers; ASA, acetylsalicylic acid; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate;
HDL, high-density lipoprotein; LCL, lower confidence interval; LDL, low-density lipoprotein; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular
outcome Results; UCL, upper confidence interval.
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recruitment into LEADER began, discussions had been
initiated in Europe on potentially relaxing BP treatment
targets [37]. It is possible that clinical practice began to
change in European centers involved in LEADER prior to
the publication of revised targets and that early imple-
mentation of this change in practice contributed to the
higher mean BP levels we observed in European partici-
pants. This explanation has recently been invoked by the
Trial Evaluating Cardiovascular Outcomes with Sitagliptin
investigators to explain a similar mean difference in SBP
and DBP (8/4mmHg) at baseline between participants with
T2DM from North America versus Western Europe [29].
Even with revised targets, rates of BP control cannot be
considered satisfactory at baseline in LEADER, as these
were achieved only in 50–54% of trial participants.
Although these rates may at first sight seem low, they are
in keeping with a contemporary pooled analysis of longi-
tudinal data from individuals with andwithout diabetes [38];
the literature suggests they are likely to be an improvement
on those that would have been observed a decade ago
[38–40]. The predictors of nonachievement of BP targets in
our analyses were broadly similar, independently of the
target figures used. The observation that BP control was
markedly better in the United States than in Europe in the
large samples of patients with T2DM and high cardiovas-
cular risk recruited into the LEADER trial prompts us to
reflect on the potential public health effects of the recent
global (European-led) relaxation of BP targets in terms of
hypertension-related cardiovascular outcomes, particularly
given that targets are infrequently achieved and BP low-
ering using currently available pharmacological agents is
well established to reduce rates of mortality and other
ASA
Statin
ARB
ACEi
Beta blocker
Macroalbuminuria
Microalbuminuria
Number of antihypertensives per medication
Insulins
Race white
Race other
Race black
Prior CVD
Region United States
Region other
Region Europe
Never smoked
Previous smoker
Current smoker
eGER >30 mI/min/1.73 m2
eGER ≥90 mI/min/1.73 m2
eGER 30–60 mI/min/1.73 m2
eGER 60–90 mI/min/1.73 m2
Female
Male
LDL per mmoI/L
HDL per mmoI/L
Totel cholesterol per mmoI/L
Creatinine per µmoI/L
Diabetes duration per 5 years
HbA 1c per %
BMI per 5 kg/m2
Age per 5 years
0.25 0.5 1 2 4
0.979 0.891; 1.077
0.746; 0.933
0.836; 1.120
0.746; 0.980
0.621; 0.799
1.051; 1.572
1.015; 1.285
1.333; 1.560
0.885; 1.066
1.130; 1.762
0.923; 1.303
0.798; 1.039
1.637; 2.112
2.104; 2.650
0.863; 1.055
0.777; 1.050
0.565; 1.778
0.490; 1.212
0.485; 1.388
0.907; 1.149
0.882; 1.173
1.023; 1.422
1.021; 1.311
0.998; 1.003
0.978; 1.038
0.994; 1.057
1.030; 1.113
1.095;1.174
0.6666
0.0015
0.6600
0.0243
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.0144
0.0274
0.5377
0.0024
0.2944
0.1628
0.3610
0.1872
0.9987
0.2579
0.4959
0.7320
0.8129
0.0255
0.0225
0.4986
0.6149
0.1088
0.0005
0.834
0.968
0.855
0.704
1.286
1.142
1.442
0.971
1.000
1.411
1.097
0.910
1.000
1.859
2.360
1.000
0.954
0.904
1.000
1.000
0.770
0.819
1.000
1.021
1.017
1.206
1.157
1.001
1.008
1.025
1.071
1.134
Odds ratio LCL; UCL P-value
–
–
–
–
–
FIGURE 3 Odds ratios for characteristics associated with blood pressure target of >140/90mmHg at baseline in the LEADER trial. ACEi, angiotensin-converting-enzyme
inhibitor; ARB, angiotensin receptor blockers; ASA, acetylsalicylic acid; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate;
HDL, high-density lipoprotein; LCL, lower confidence interval; LDL, low-density lipoprotein; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular
outcome Results; UCL, upper confidence interval.
Petrie et al.
1146 www.jhypertension.com Volume 34  Number 6  June 2016
T
A
B
LE
2
.
B
a
se
li
n
e
ch
a
ra
ct
e
ri
st
ic
s
o
f
p
a
rt
ic
ip
a
n
ts
in
th
e
li
ra
g
lu
ti
d
e
e
ff
e
ct
a
n
d
a
ct
io
n
in
d
ia
b
e
te
s:
e
v
a
lu
a
ti
o
n
o
f
ca
rd
io
v
a
sc
u
la
r
o
u
tc
o
m
e
re
su
lt
s
tr
ia
l
in
re
la
ti
o
n
to
p
re
v
io
u
s
la
n
d
m
a
rk
tr
ia
ls
T
ri
a
l
n
a
m
e
LE
A
D
E
R
E
X
A
M
IN
E
[2
2
]
S
A
V
O
R
-T
IM
I
5
3
[2
3
,2
4
]
A
C
C
O
R
D
[2
5
]
R
E
C
O
R
D
[2
6
]
A
D
V
A
N
C
E
[2
]
P
R
O
A
C
T
IV
E
[2
7
]
U
K
P
D
S
G
lu
co
se
[2
8
]
U
K
P
D
S
B
P
[1
]
G
lu
co
se
B
P
N
9
3
4
0
5
3
8
0
1
6
4
9
2
1
0
2
5
1
4
7
3
3
4
4
4
7
1
1
1
4
0
5
2
3
8
3
8
6
7
1
1
4
8
A
g
e
(y
ea
rs
)
6
4
.3

7
.2
6
1
.0

6
5

8
.5
6
2
.2

6
.8
5
8
.5

8
.3
6
6

6
.0
6
1
.8

7
.7
5
3

8
.6
5
6
.4

8
.1
Se
x
(%
m
al
e)
6
4
.3
6
7
.9
6
7
.0
6
1
.4
5
2
.3
5
1
.6
5
7
6
7
6
1
5
4
R
ac
e
(%
w
h
it
e)
7
7
.5
7
2
.7
7
5
.3
6
4
.5
6
0
.5
9
8
.9
-
9
9
8
1
8
7
C
V
D
(%
)
8
1
1
0
0
7
8
3
5
3
4
3
0
3
2
1
0
0
–
–
D
u
ra
ti
o
n
(y
ea
rs
)
1
2
.7

8
.0
7
.2
(2
.6
–
1
3
.8
)
1
0
.3
(5
.2
–
1
6
.7
)
1
0
(5
–
1
5
)
7
.1

5
.0
8
.0

6
.4
8
(4
–
1
4
)
–
2
.6
(1
–
4
.3
)
H
b
A
1
c
(%
)
8
.7

1
.5
8
.0

1
.1
8
.0

1
.4
8
.3

1
.1
7
.9

0
.7
7
.5

1
.6
4
7
.9
(7
.0
–
8
.9
)
6
.2

1
.2
6
.9

1
.6
B
M
I
(k
g
/m
2
)
3
2
.5

6
.3
2
8
.7
3
1
.2
3
2
.2

5
.5
3
1
.6

4
.8
2
8

5
3
1

4
.8
2
7
.5

5
.2
2
9
.6

5
.5
eG
FR
(m
l/m
in
p
er
1
.7
3
m
2
)
8
1
.5

2
8
.0
7
1
.2
7
2
.6

2
2
.6
9
1
.6

2
8
.8
–
–
–
–
–
eG
FR
<
6
0
(%
)
2
1
.8
2
9
.1
7
2
.6
–
–
–
–
–
–
C
re
at
in
in
e
(m
m
o
l/l
)
8
6

3
7
.0
–
–
7
9

1
7
.7
6
5
8
7

2
6
7
9
(6
8
–
9
2
)
8
1
(6
7
–
1
0
0
)
–
M
ic
ro
al
b
u
m
in
u
ri
a
(%
)
2
0
1
9
2
7
4
6
7
–
A
C
R
(m
g
/m
m
o
l)
3
.0
–
1
.8
(0
.7
–
7
.7
)
–
1
4
.3
(6
.9
–
4
4
.8
)
–
1
5
(7
–
4
0
)
–
–
–
H
yp
er
te
n
si
o
n
(%
)
9
0
.0
8
3
.1
8
1
.8
–
8
0
6
9
7
6
–
–
SB
P
(m
m
H
g
)
1
3
8

1
8
.6
–
–
1
3
6

1
7
.1
1
3
9

1
5
.8
1
3
9

1
5
1
4
5

2
2
1
4
4

1
8
1
3
5

2
0
1
6
0

1
9
D
B
P
(m
m
H
g
)
7
8

1
1
–
–
7
5

1
1
7
6

1
0
8
3

8
8
1

1
1
8
3

1
0
8
2

1
0
9
4

1
0
A
n
ti
h
yp
er
te
n
si
ve
m
ed
ic
at
io
n
s
(%
)
9
2
–
–
8
5
8
7
–
7
5
1
8
3
7
A
C
E
in
h
ib
it
o
r
(%
)
4
9
–
5
4
5
3
5
2
4
3
(o
r
A
R
B
)
4
3
6
3
–
–
A
R
B
(%
)
3
1
.7
–
2
7
.9
–
1
6
.9
–
6
7
–
–
b
-b
lo
ck
er
(%
)
5
5
–
6
2
2
9
2
6
2
1
2
5
5
5
–
–
Sm
o
ke
r
(%
)
1
2
1
4
1
3
1
4
1
3
1
6
1
4
1
3
3
1
2
3
In
su
lin
(%
)
4
2
3
0
4
1
3
5
3
7
0
2
4
2
–
2
4
St
at
in
s
(%
)
9
0
9
1
7
8
6
2
6
5
1
9
2
9
4
3
–
–
To
ta
l
ch
o
le
st
er
o
l
(m
m
o
l/l
)
4
.4

1
.1
7
4
.0

1
.1
3
–
4
.7

1
.0
8
5
.0

1
.1
6
–
5
.2

1
.2
0
5
.4

1
.1
0
–
LD
L
ch
o
le
st
er
o
l
(m
m
o
l/l
)
2
.3

0
.9
2
2
.0
4
–
2
.7

0
.8
7
2
.5

1
.0
1
3
.3
0
.9
3
.1

1
.0
3
2
.9
(2
.3
–
3
.5
)
3
.5

1
.0
2
–
H
D
L
ch
o
le
st
er
o
l
(m
m
o
l/l
)
1
.2

0
.3
2
1
.1
2
–
1
.1

0
.2
9
1
.2

0
.3
7
1
.2

0
.3
1
.3

1
.0
3
1
.1
(0
.9
–
1
.3
)
1
.1

0
.2
4
–
 D
at
a
ar
e
sh
o
w
n
as
m
ea
n

SD
o
r
m
ed
ia
n
w
it
h
in
te
rq
u
ar
ti
le
ra
n
g
es
o
r
ra
n
g
e.
A
C
E,
an
g
io
te
n
si
n
-c
o
n
ve
rt
in
g
-e
n
zy
m
e;
A
C
R
,
al
b
u
m
in
:c
re
at
in
in
e
ra
ti
o
;
A
R
B
,
an
g
io
te
n
si
n
re
ce
p
to
r
b
lo
ck
er
s;
B
P,
b
lo
o
d
p
re
ss
u
re
;
C
V
D
,
ca
rd
io
va
sc
u
la
r
d
is
ea
se
;
eG
FR
,
es
ti
m
at
ed
g
lo
m
er
u
la
r
fi
lt
ra
ti
o
n
ra
te
;
H
D
L,
h
ig
h
-d
en
si
ty
lip
o
p
ro
te
in
;
LD
L,
lo
w
-
d
en
si
ty
lip
o
p
ro
te
in
;
LE
A
D
ER
,
Li
ra
g
lu
ti
d
e
Ef
fe
ct
an
d
A
ct
io
n
in
D
ia
b
et
es
:
Ev
al
u
at
io
n
o
f
ca
rd
io
va
sc
u
la
r
o
u
tc
o
m
e
R
es
u
lt
s.
Blood pressure control in type 2 diabetes
Journal of Hypertension www.jhypertension.com 1147
complications [41]. The SPRINT trial has recently high-
lighted the benefits of BP-lowering in nondiabetic individ-
uals and hence rekindled enthusiasm for more intensive BP
targets in diabetes [42]. This has reopened discussion of the
results of the ACCORD trial [25] which provided a key
stimulus for relaxation of previous BP targets in individuals
with T2DM.
The strength of the present analysis is the large number
of patients studied at baseline in a clinical trial setting, with
data collection according to a standard protocol and use of
a central laboratory. Moreover, multiracial sampling of
individuals from a global population favors the general-
izability of our findings. However, as acknowledged above,
selection bias at study sites could have influenced
our results. Furthermore, measurement of BP was cross-
sectional rather than longitudinal and some details of the
methods of measurement within individual sites were
not available.
It is clear from the present analysis that BP targets are too
infrequently achieved in many individuals with T2DM.
Many mechanisms for resistance to therapy have been
identified and reviewed, including higher baseline BP
because of obesity, activation of the sympathetic nervous
system, changes in central hemodynamics [43], volume
overload, and renin–angiotensin system activation [41].
Glucose-lowering therapies that also possess BP-lowering
effects may therefore have an attractive profile from a CVD
prevention perspective, as demonstrated by a reduction in
cardiovascular death with the SGLT-2 inhibitor with empa-
gliflozin as recently reported in the EMPA-REG trial [44].
GLP-1 receptor agonists and SGLT-2 inhibitors reduce BP
in part via weight reduction, but also influence renal
sodium handling [12,45], whereas GLP-1 receptor agonists
may also have direct effects on the vasculature [12]. It is
reasonable to speculate that such agents may facilitate the
long-term achievement of BP targets in people with hyper-
tension and T2DM treated with multiple agents, although as
shown in the recent ELIXA trial, this will not necessarily
translate into cardiovascular benefit [46]. Moreover, it
should also be noted that in the LEADER trial, a ‘standard
of care’ approach was used, that is, any effect of GLP-1
therapy on BP between the groups as randomized over the
full duration of the trial may ultimately be offset by
additional therapy in the placebo arm.
In summary, the present data highlight that, even with
modern antihypertensive therapy, adequate control of BP is
not achieved in many high-risk individuals with T2DM,
particularly outside North America. Longitudinal data from
the LEADER trial may provide further insights into BP
control in relation to cardiovascular outcomes in this
condition.
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Reviewers’ Summary Evaluations
Reviewer 1
The study illustrates baseline characteristics of type 2 dia-
betic patients included in the LEADER 4 trial, thus reporting
that the overall blood pressure control rate (<140/90
mmHg) is relatively poorly achieved, particularly when
considering the more intensive blood pressure targets
(<130/80 mmHg). This is of potential clinical relevance,
since the issue concerning the most appropriate blood
pressure targets to be achieved in high-risk hypertensive
patients with diabetes is still actively debated. For these
reasons, a closer analysis of baseline cardiovascular risk
stratification might be of help for properly interpreting the
future outcomes of this trial.
Reviewer 2
This study presents data from the LEADER trial, confirming
the relatively poor levels of blood pressure control
achieved in type 2 diabetes patients at high cardiovascular
risk, especially according to more strict BP targets and in
countries other than North America. Despite the fact that
comparability is limited by the nature of a multicenter trial,
with different sampling schemes, this study provides an
informative contemporary, inter-region perspective on BP
control among diabetes patients.
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